Pediatrix director granted 7,196 restricted shares
McEachin Thomas reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
McEachin Thomas reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group director Thomas McEachin reported an equity grant and updated holdings. He received a grant of 7,196 restricted shares of Common Stock at a price of $0.00 per share as an annual equity award under the Amended and Restated 2008 Incentive Compensation Plan. These restricted shares will vest on May 7, 2027. Following the grant, he directly holds 18,623 common shares. Separately, a trust titled the Thomas A. McEachin Living Trust dated April 17, 2025 holds 54,646 common shares, for which McEachin and his spouse serve as trustees and beneficiaries.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 7,196 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
Footnotes (2)
- F1. Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award. Shares will vest on May 7, 2027.
- F2. The reporting person and his spouse are trustees and beneficiaries of the trust that holds the reported securities.
Key Figures
Key Terms
Amended and Restated 2008 Incentive Compensation Plan financial
annual equity award financial
beneficiaries financial
trustees financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Pediatrix (MD) director Thomas McEachin report in this Form 4?
Is Thomas McEachin’s Pediatrix (MD) Form 4 a market purchase or sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.